Danaher (NYSE:DHR)‘s stock had its “buy” rating reissued by equities researchers at Robert W. Baird in a note issued to investors on Friday.
A number of other research analysts also recently issued reports on DHR. Goldman Sachs Group restated a “neutral” rating and set a $83.00 price target on shares of Danaher in a research note on Tuesday, September 26th. Evercore ISI began coverage on Danaher in a research note on Wednesday, January 3rd. They set an “outperform” rating on the stock. Royal Bank of Canada restated a “hold” rating and set a $96.00 price target on shares of Danaher in a research note on Thursday, January 4th. Zacks Investment Research cut Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, Cowen reaffirmed a “buy” rating and set a $90.00 price objective on shares of Danaher in a research report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $94.91.
Danaher (NYSE:DHR) opened at $98.59 on Friday. The stock has a market capitalization of $68,580.00, a P/E ratio of 29.34, a P/E/G ratio of 2.07 and a beta of 1.03. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. Danaher has a 12 month low of $78.97 and a 12 month high of $98.88.
In related news, SVP Daniel Raskas sold 37,870 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Robert S. Lutz sold 11,189 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now directly owns 18,314 shares of the company’s stock, valued at $1,678,661.24. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock valued at $25,218,813 over the last ninety days. 12.20% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DHR. Point72 Asset Management L.P. increased its position in Danaher by 276.8% during the third quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock worth $225,332,000 after buying an additional 1,929,751 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Danaher by 16,410.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after buying an additional 1,476,901 shares in the last quarter. Findlay Park Partners LLP increased its position in Danaher by 52.9% during the third quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after buying an additional 1,425,000 shares in the last quarter. Koch Industries Inc. increased its position in Danaher by 29,127.3% during the second quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after buying an additional 1,399,859 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Danaher by 86.1% during the third quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock worth $256,136,000 after buying an additional 1,393,165 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.